Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Fruquintinib boosts survival in mCRC patients
August 2018
SHARING OPTIONS:

As announced recently by the Journal of the American Medical Association, there was good news from a randomized clinical trial of fruquintinib in 416 Chinese patients with metastatic colorectal cancer (mCRC) who had seen their cancer progress after at least two lines of chemotherapy: fruquintinib treatment led to a statistically significant increase in patients’ overall survival compared to placebo. Patients who received oral fruquintinib in the FRESCO trial had a median survival time of 9.3 months, compared to 6.6 months in the placebo arm. Median progression-free survival (PFS) improved as well, with fruquintinib patients displaying a median PFS of 3.7 months vs. 1.8 months in the placebo arm. About 61.2 percent of patients receiving fruquintinib experienced grades 3 and 4 treatment-emergent adverse events, with 15.5 percent reporting serious adverse events and 14.4 percent requiring hospitalization.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.